|
1
|
Lazarou J, Pomeranz BH and Corey PN:
Incidence of adverse drug reactions in hospitalized patients: a
meta-analysis of prospective studies. JAMA. 279:1200–1205. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dormann H, Neubert A, Criegee-Rieck M, et
al: Readmissions and adverse drug reactions in internal medicine:
the economic impact. J Intern Med. 255:653–663. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shastry BS: Pharmacogenetics and the
concept of individualized medicine. Pharmacogenomics J. 6:16–21.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sachidanandam R, Weissman D, Schmidt SC,
et al; International SNP Map Working Group. A map of human genome
sequence variation containing 1.42 million single nucleotide
polymorphisms. Nature. 409:928–933. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Evans WE and Relling MV: Pharmacogenomics:
translating functional genomics into rational therapeutics.
Science. 286:487–491. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Evans WE and Johnson JA: Pharmacogenomics:
the inherited basis for interindividual differences in drug
response. Annu Rev Genomics Hum Genet. 2:9–39. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
McLeod HL and Evans WE: Pharmacogenomics:
unlocking the human genome for better drug therapy. Annu Rev
Pharmacol Toxicol. 41:101–121. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yates CR, Krynetski EY, Loennechen T, et
al: Molecular diagnosis of thiopurine S-methyltransferase
deficiency: genetic basis for azathioprine and mercaptopurine
intolerance. Ann Intern Med. 126:608–614. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Evans WE and McLeod HL: Pharmacogenomics -
drug disposition, drug targets, and side effects. N Engl J Med.
348:538–549. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Johnson JA: Pharmacogenetics: potential
for individualized drug therapy through genetics. Trends Genet.
19:660–666. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guttmacher AE and Collins FS: Welcome to
the genomic era. N Engl J Med. 349:996–998. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zineh I, Gerhard T, Aquilante CL,
Beitelshees AL, Beasley BN and Hartzema AG: Availability of
pharmacogenomics-based prescribing information in drug package
inserts for currently approved drugs. Pharmacogenomics J.
4:354–358. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schmitz G, Aslanidis C and Lackner KJ:
Pharmacogenomics: implications for laboratory medicine. Clin Chim
Acta. 308:43–53. 2001. View Article : Google Scholar
|
|
14
|
Collins FS, Green ED, Guttmacher AE, Guyer
MS, et al: A vision for the future of genomics research. Nature.
422:835–847. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ragoussis J: Genotyping technologies for
genetic research. Annu Rev Genomics Hum Genet. 10:117–133. 2009.
View Article : Google Scholar
|
|
16
|
Kapoor G, Maitra A and Brahmachari V:
Application of SNaPshot for analysis of thiopurine
methyltransferase gene polymorphism. Indian J Med Res. 129:500–505.
2009.PubMed/NCBI
|
|
17
|
Fan JB, Gunderson KL, Bibikova M, et al:
Illumina universal bead arrays. Methods Enzymol. 410:57–73. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lin CH, Yeakley JM, McDaniel TK and Shen
R: Medium- to high-throughput SNP genotyping using VeraCode
microbeads. Methods Mol Biol. 496:129–142. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sanchez JJ, Borsting C, Hallenberg C,
Buchard A, Hernandez A and Morling N: Multiplex PCR and
minisequencing of SNPs - a model with 35 Y chromosome SNPs.
Forensic Sci Int. 137:74–84. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hulot JS, Bura A, Villard E, et al:
Cytochrome P450 2C19 loss-of-function polymorphism is a major
determinant of clopidogrel responsiveness in healthy subjects.
Blood. 108:2244–2247. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Savi P, Herbert JM, Pflieger AM, et al:
Importance of hepatic metabolism in the antiaggregating activity of
the thienopyridine clopidogrel. Biochem Pharmacol. 44:527–532.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Savi P, Combalbert J, Gaich C, et al: The
antiaggregating activity of clopidogrel is due to a metabolic
activation by the hepatic cytochrome P450-1A. Thromb Haemost.
72:313–317. 1994.PubMed/NCBI
|
|
23
|
Hollopeter G, Jantzen HM, Vincent D, et
al: Identification of the platelet ADP receptor targeted by
antithrombotic drugs. Nature. 409:202–207. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Derijks LJ, Gilissen LP, Engels LG, et al:
Pharmacokinetics of 6-thioguanine in patients with inflammatory
bowel disease. Ther Drug Monit. 28:45–50. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Heneghan MA, Allan ML, Bornstein JD, Muir
AJ and Tendler DA: Utility of thiopurine methyltransferase
genotyping and phenotyping, and measurement of azathioprine
metabolites in the management of patients with autoimmune
hepatitis. J Hepatol. 45:584–591. 2006. View Article : Google Scholar
|
|
26
|
Roman M, Cabaleiro T, Ochoa D, et al:
Validation of a genotyping method for analysis of TPMT
polymorphisms. Clin Ther. 34:878–884. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hakooz N, Arafat T, Payne D, et al:
Genetic analysis of thiopurine methyltransferase polymorphism in
the Jordanian population. Eur J Clin Pharmacol. 66:999–1003. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Amstutz U, Froehlich TK and Largiader CR:
Dihydropyrimidine dehydrogenase gene as a major predictor of severe
5-fluorouracil toxicity. Pharmacogenomics. 12:1321–1336. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Meyerhardt JA and Mayer RJ: Systemic
therapy for colorectal cancer. N Engl J Med. 352:476–487. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ezzeldin H and Diasio R: Dihydropyrimidine
dehydrogenase deficiency, a pharmacogenetic syndrome associated
with potentially life-threatening toxicity following 5-fluorouracil
administration. Clin Colorectal Cancer. 4:181–189. 2004. View Article : Google Scholar
|
|
31
|
van Kuilenburg AB, Maring JG, Schalhorn A,
et al: Pharmacokinetics of 5-fluorouracil in patients heterozygous
for the IVS14+1G>A mutation in the dihydropyrimidine
dehydrogenase gene. Nucleosides Nucleotides Nucleic Acids.
27:692–698. 2008.
|
|
32
|
Suppiah V, Moldovan M, Ahlenstiel G, et
al: IL28B is associated with response to chronic hepatitis C
interferon-alpha and ribavirin therapy. Nat Genet. 41:1100–1104.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tanaka Y, Nishida N, Sugiyama M, et al:
Genome-wide association of IL28B with response to pegylated
interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat
Genet. 41:1105–1109. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rauch A, Kutalik Z, Descombes P, et al:
Genetic variation in IL28B is associated with chronic hepatitis C
and treatment failure: a genome-wide association study.
Gastroenterology. 138:1338–1345. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Glurich I, Burmester JK and Caldwell MD:
Understanding the pharmacogenetic approach to warfarin dosing.
Heart Fail Rev. 15:239–248. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schalekamp T, Brasse BP, Roijers JF, et
al: VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation
status: interaction between both genotypes affects dose
requirement. Clin Pharmacol Ther. 81:185–193. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wadelius M, Chen LY, Eriksson N, et al:
Association of warfarin dose with genes involved in its action and
metabolism. Hum Genet. 121:23–34. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sconce EA, Khan TI, Wynne HA, et al: The
impact of CYP2C9 and VKORC1 genetic polymorphism and patient
characteristics upon warfarin dose requirements: proposal for a new
dosing regimen. Blood. 106:2329–2333. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
D’Andrea G, D’Ambrosio RL, Di Perna P, et
al: A polymorphism in the VKORC1 gene is associated with an
interindividual variability in the dose-anticoagulant effect of
warfarin. Blood. 105:645–649. 2005.PubMed/NCBI
|
|
40
|
Schalekamp T, Brasse BP, Roijers JF, et
al: VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation
status: interaction between both genotypes affects
overanticoagulation. Clin Pharmacol Ther. 80:13–22. 2006.
View Article : Google Scholar
|
|
41
|
Wang D, Chen H, Momary KM, Cavallari LH,
Johnson JA and Sadee W: Regulatory polymorphism in vitamin K
epoxide reductase complex subunit 1 (VKORC1) affects gene
expression and warfarin dose requirement. Blood. 112:1013–1021.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Limdi NA, Arnett DK, Goldstein JA, et al:
Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation
attainment and maintenance among European-Americans and
African-Americans. Pharmacogenomics. 9:511–526. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fuerst D, Parmar S, Schumann C, et al: HLA
polymorphisms influence the development of skin rash arising from
treatment with EGF receptor inhibitors. Pharmacogenomics.
13:1469–1476. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Melis R, Lewis T, Millson A, et al: Copy
number variation and incomplete linkage disequilibrium interfere
with the HCP5 genotyping assay for abacavir hypersensitivity. Genet
Test Mol Biomarkers. 16:1111–1114. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Maekawa K, Nishikawa J, Kaniwa N, et al:
Development of a rapid and inexpensive assay for detecting a
surrogate genetic polymorphism of HLA-B*58:01: a
partially predictive but useful biomarker for allopurinol-related
Stevens-Johnson syndrome/toxic epidermal necrolysis in Japanese.
Drug Metab Pharmacokinet. 27:447–450. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Leeder JS: Mechanisms of idiosyncratic
hypersensitivity reactions to antiepileptic drugs. Epilepsia.
39(Suppl 7): S8–S16. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wu XT, Hu FY, An DM, et al: Association
between carbamazepine-induced cutaneous adverse drug reactions and
the HLA-B*1502 allele among patients in central China.
Epilepsy Behav. 19:405–408. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hung SI, Chung WH, Liu ZS, et al: Common
risk allele in aromatic antiepileptic-drug induced Stevens-Johnson
syndrome and toxic epidermal necrolysis in Han Chinese.
Pharmacogenomics. 11:349–356. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chen P, Lin JJ, Lu CS, et al:
Carbamazepine-induced toxic effects and HLA-B*1502
screening in Taiwan. N Engl J Med. 364:1126–1133. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang Y, Wang J, Zhao LM, et al: Strong
association between HLA-B*1502 and carbamazepine-induced
Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland
Han Chinese patients. Eur J Clin Pharmacol. 67:885–887.
2011.PubMed/NCBI
|
|
51
|
Wang Q, Zhou JQ, Zhou LM, et al:
Association between HLA-B*1502 allele and
carbamazepine-induced severe cutaneous adverse reactions in Han
people of southern China mainland. Seizure. 20:446–448. 2011.
|
|
52
|
Colombo S, Rauch A, Rotger M, et al: The
HCP5 single-nucleotide polymorphism: a simple screening tool for
prediction of hypersensitivity reaction to abacavir. J Infect Dis.
198:864–867. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sanchez-Giron F, Villegas-Torres B,
Jaramillo-Villafuerte K, et al: Association of the genetic marker
for abacavir hypersensitivity HLA-B*5701 with HCP5
rs2395029 in Mexican Mestizos. Pharmacogenomics. 12:809–814. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ross CJ, Katzov-Eckert H, Dube MP, et al:
Genetic variants in TPMT and COMT are associated with hearing loss
in children receiving cisplatin chemotherapy. Nat Genet.
41:1345–1349. 2009. View
Article : Google Scholar : PubMed/NCBI
|
